Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies
Abstract Our review summarizes the five main studies conducted to evaluate the efficacy and pharmacokinetics of ropinirole prolonged release (PR) in Parkinson's disease (PD). The PR formulation was developed with Geomatrix coating technology in order to obtain constant pharmacokinetics througho...
Gespeichert in:
| Veröffentlicht in: | Parkinsonism & related disorders 2009-12, Vol.15, p.S85-S92 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S92 |
|---|---|
| container_issue | |
| container_start_page | S85 |
| container_title | Parkinsonism & related disorders |
| container_volume | 15 |
| creator | Onofrj, M Bonanni, L De Angelis, M.V Anzellotti, F Ciccocioppo, F Thomas, A |
| description | Abstract Our review summarizes the five main studies conducted to evaluate the efficacy and pharmacokinetics of ropinirole prolonged release (PR) in Parkinson's disease (PD). The PR formulation was developed with Geomatrix coating technology in order to obtain constant pharmacokinetics throughout 24 hours. The areas under the curve were not significantly different from those observed with similar doses of ropinirole immediate-release (IR) formulation, administered 3 times a day, but concentration fluctuations were less for ropinirole PR (2-fold vs 5-fold). The efficacy study of the PR versus IR formulations showed non-inferiority of the PR formulation, similar tolerability and feasibility of overnight switches, and indicated that the optimal doses of ropinirole in patients with de novo PD is in the range of 8–12 mg/day. The efficacy study in PD patients with motor fluctuations treated with l -dopa showed that adding ropinirole PR significantly reduced “off” time and increased “on” time in comparison with placebo. The study with ropinirole as an add-on to l -dopa showed a reduced incidence of dyskinesias. |
| doi_str_mv | 10.1016/S1353-8020(09)70842-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733657672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1353802009708429</els_id><sourcerecordid>733657672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-1c807686b73b61c3fa0c4d4d4aed90229f3714bcb40e05f66d133ffab00052303</originalsourceid><addsrcrecordid>eNqFkE1vFSEUhifGxtbqT9Cwsy6mHmCAwYWmafxKbuJCXRMGDpU6d5jCjKb_Xu69rQtjYlhATt7zHM7TNM8onFOg8tUXygVve2BwBvqlgr5jrX7QnNBe8VZQJh_W933kuHlcyjUAKAH8UXPMgDIupDhpbjZpuiLf7RjaMQYkdvJkzmmsVfRtxhFtQeLTbLdxQpLR4bykTOxVmmJZymtia_FnxF8kBZLTHKdY2_EfkLKsPmJ50hwFOxZ8enefNt_ev_t6-bHdfP7w6fJi07qO6qWlrgclezkoPkjqeLDgOl-PRa-BMR24ot3ghg4QRJDSU85DsEPdUjAO_LR5ceDWn9ysWBazjcXhONoJ01qM4lwKJRWrSXFIupxKyRjMnOPW5ltDwexkm71sszNpQJu9bKNr3_O7CeuwRf-n695uDbw9BLDuWR1lU1zEyaGPVeRifIr_HfHmL4Ibq2Fnxx94i-U6rXmqEg01hRk4QHYM0HuC5r8Bw8SkxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733657672</pqid></control><display><type>article</type><title>Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Onofrj, M ; Bonanni, L ; De Angelis, M.V ; Anzellotti, F ; Ciccocioppo, F ; Thomas, A</creator><creatorcontrib>Onofrj, M ; Bonanni, L ; De Angelis, M.V ; Anzellotti, F ; Ciccocioppo, F ; Thomas, A</creatorcontrib><description>Abstract Our review summarizes the five main studies conducted to evaluate the efficacy and pharmacokinetics of ropinirole prolonged release (PR) in Parkinson's disease (PD). The PR formulation was developed with Geomatrix coating technology in order to obtain constant pharmacokinetics throughout 24 hours. The areas under the curve were not significantly different from those observed with similar doses of ropinirole immediate-release (IR) formulation, administered 3 times a day, but concentration fluctuations were less for ropinirole PR (2-fold vs 5-fold). The efficacy study of the PR versus IR formulations showed non-inferiority of the PR formulation, similar tolerability and feasibility of overnight switches, and indicated that the optimal doses of ropinirole in patients with de novo PD is in the range of 8–12 mg/day. The efficacy study in PD patients with motor fluctuations treated with l -dopa showed that adding ropinirole PR significantly reduced “off” time and increased “on” time in comparison with placebo. The study with ropinirole as an add-on to l -dopa showed a reduced incidence of dyskinesias.</description><identifier>ISSN: 1353-8020</identifier><identifier>EISSN: 1873-5126</identifier><identifier>DOI: 10.1016/S1353-8020(09)70842-9</identifier><identifier>PMID: 20123565</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Delayed-Action Preparations - administration & dosage ; Delayed-Action Preparations - pharmacokinetics ; Dopamine Agonists - administration & dosage ; Dopamine Agonists - pharmacokinetics ; Drug Therapy, Combination ; Dyskinesia, Drug-Induced - drug therapy ; Dyskinesia, Drug-Induced - metabolism ; Half-Life ; Humans ; Indoles - administration & dosage ; Indoles - pharmacokinetics ; Neurology ; Parkinson Disease - drug therapy ; Parkinson Disease - metabolism ; Parkinson's disease ; Pharmacokinetics ; Randomized Controlled Trials as Topic - methods ; Ropinirole</subject><ispartof>Parkinsonism & related disorders, 2009-12, Vol.15, p.S85-S92</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><rights>Copyright 2009 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-1c807686b73b61c3fa0c4d4d4aed90229f3714bcb40e05f66d133ffab00052303</citedby><cites>FETCH-LOGICAL-c419t-1c807686b73b61c3fa0c4d4d4aed90229f3714bcb40e05f66d133ffab00052303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S1353-8020(09)70842-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20123565$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Onofrj, M</creatorcontrib><creatorcontrib>Bonanni, L</creatorcontrib><creatorcontrib>De Angelis, M.V</creatorcontrib><creatorcontrib>Anzellotti, F</creatorcontrib><creatorcontrib>Ciccocioppo, F</creatorcontrib><creatorcontrib>Thomas, A</creatorcontrib><title>Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies</title><title>Parkinsonism & related disorders</title><addtitle>Parkinsonism Relat Disord</addtitle><description>Abstract Our review summarizes the five main studies conducted to evaluate the efficacy and pharmacokinetics of ropinirole prolonged release (PR) in Parkinson's disease (PD). The PR formulation was developed with Geomatrix coating technology in order to obtain constant pharmacokinetics throughout 24 hours. The areas under the curve were not significantly different from those observed with similar doses of ropinirole immediate-release (IR) formulation, administered 3 times a day, but concentration fluctuations were less for ropinirole PR (2-fold vs 5-fold). The efficacy study of the PR versus IR formulations showed non-inferiority of the PR formulation, similar tolerability and feasibility of overnight switches, and indicated that the optimal doses of ropinirole in patients with de novo PD is in the range of 8–12 mg/day. The efficacy study in PD patients with motor fluctuations treated with l -dopa showed that adding ropinirole PR significantly reduced “off” time and increased “on” time in comparison with placebo. The study with ropinirole as an add-on to l -dopa showed a reduced incidence of dyskinesias.</description><subject>Animals</subject><subject>Delayed-Action Preparations - administration & dosage</subject><subject>Delayed-Action Preparations - pharmacokinetics</subject><subject>Dopamine Agonists - administration & dosage</subject><subject>Dopamine Agonists - pharmacokinetics</subject><subject>Drug Therapy, Combination</subject><subject>Dyskinesia, Drug-Induced - drug therapy</subject><subject>Dyskinesia, Drug-Induced - metabolism</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Indoles - administration & dosage</subject><subject>Indoles - pharmacokinetics</subject><subject>Neurology</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson's disease</subject><subject>Pharmacokinetics</subject><subject>Randomized Controlled Trials as Topic - methods</subject><subject>Ropinirole</subject><issn>1353-8020</issn><issn>1873-5126</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1vFSEUhifGxtbqT9Cwsy6mHmCAwYWmafxKbuJCXRMGDpU6d5jCjKb_Xu69rQtjYlhATt7zHM7TNM8onFOg8tUXygVve2BwBvqlgr5jrX7QnNBe8VZQJh_W933kuHlcyjUAKAH8UXPMgDIupDhpbjZpuiLf7RjaMQYkdvJkzmmsVfRtxhFtQeLTbLdxQpLR4bykTOxVmmJZymtia_FnxF8kBZLTHKdY2_EfkLKsPmJ50hwFOxZ8enefNt_ev_t6-bHdfP7w6fJi07qO6qWlrgclezkoPkjqeLDgOl-PRa-BMR24ot3ghg4QRJDSU85DsEPdUjAO_LR5ceDWn9ysWBazjcXhONoJ01qM4lwKJRWrSXFIupxKyRjMnOPW5ltDwexkm71sszNpQJu9bKNr3_O7CeuwRf-n695uDbw9BLDuWR1lU1zEyaGPVeRifIr_HfHmL4Ibq2Fnxx94i-U6rXmqEg01hRk4QHYM0HuC5r8Bw8SkxQ</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Onofrj, M</creator><creator>Bonanni, L</creator><creator>De Angelis, M.V</creator><creator>Anzellotti, F</creator><creator>Ciccocioppo, F</creator><creator>Thomas, A</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20091201</creationdate><title>Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies</title><author>Onofrj, M ; Bonanni, L ; De Angelis, M.V ; Anzellotti, F ; Ciccocioppo, F ; Thomas, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-1c807686b73b61c3fa0c4d4d4aed90229f3714bcb40e05f66d133ffab00052303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Delayed-Action Preparations - administration & dosage</topic><topic>Delayed-Action Preparations - pharmacokinetics</topic><topic>Dopamine Agonists - administration & dosage</topic><topic>Dopamine Agonists - pharmacokinetics</topic><topic>Drug Therapy, Combination</topic><topic>Dyskinesia, Drug-Induced - drug therapy</topic><topic>Dyskinesia, Drug-Induced - metabolism</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Indoles - administration & dosage</topic><topic>Indoles - pharmacokinetics</topic><topic>Neurology</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson's disease</topic><topic>Pharmacokinetics</topic><topic>Randomized Controlled Trials as Topic - methods</topic><topic>Ropinirole</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Onofrj, M</creatorcontrib><creatorcontrib>Bonanni, L</creatorcontrib><creatorcontrib>De Angelis, M.V</creatorcontrib><creatorcontrib>Anzellotti, F</creatorcontrib><creatorcontrib>Ciccocioppo, F</creatorcontrib><creatorcontrib>Thomas, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Parkinsonism & related disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Onofrj, M</au><au>Bonanni, L</au><au>De Angelis, M.V</au><au>Anzellotti, F</au><au>Ciccocioppo, F</au><au>Thomas, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies</atitle><jtitle>Parkinsonism & related disorders</jtitle><addtitle>Parkinsonism Relat Disord</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>15</volume><spage>S85</spage><epage>S92</epage><pages>S85-S92</pages><issn>1353-8020</issn><eissn>1873-5126</eissn><abstract>Abstract Our review summarizes the five main studies conducted to evaluate the efficacy and pharmacokinetics of ropinirole prolonged release (PR) in Parkinson's disease (PD). The PR formulation was developed with Geomatrix coating technology in order to obtain constant pharmacokinetics throughout 24 hours. The areas under the curve were not significantly different from those observed with similar doses of ropinirole immediate-release (IR) formulation, administered 3 times a day, but concentration fluctuations were less for ropinirole PR (2-fold vs 5-fold). The efficacy study of the PR versus IR formulations showed non-inferiority of the PR formulation, similar tolerability and feasibility of overnight switches, and indicated that the optimal doses of ropinirole in patients with de novo PD is in the range of 8–12 mg/day. The efficacy study in PD patients with motor fluctuations treated with l -dopa showed that adding ropinirole PR significantly reduced “off” time and increased “on” time in comparison with placebo. The study with ropinirole as an add-on to l -dopa showed a reduced incidence of dyskinesias.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>20123565</pmid><doi>10.1016/S1353-8020(09)70842-9</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1353-8020 |
| ispartof | Parkinsonism & related disorders, 2009-12, Vol.15, p.S85-S92 |
| issn | 1353-8020 1873-5126 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733657672 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Delayed-Action Preparations - administration & dosage Delayed-Action Preparations - pharmacokinetics Dopamine Agonists - administration & dosage Dopamine Agonists - pharmacokinetics Drug Therapy, Combination Dyskinesia, Drug-Induced - drug therapy Dyskinesia, Drug-Induced - metabolism Half-Life Humans Indoles - administration & dosage Indoles - pharmacokinetics Neurology Parkinson Disease - drug therapy Parkinson Disease - metabolism Parkinson's disease Pharmacokinetics Randomized Controlled Trials as Topic - methods Ropinirole |
| title | Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T01%3A09%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20half-life%20and%20prolonged-release%20dopamine%20receptor%20agonists:%20a%20review%20of%20ropinirole%20prolonged-release%20studies&rft.jtitle=Parkinsonism%20&%20related%20disorders&rft.au=Onofrj,%20M&rft.date=2009-12-01&rft.volume=15&rft.spage=S85&rft.epage=S92&rft.pages=S85-S92&rft.issn=1353-8020&rft.eissn=1873-5126&rft_id=info:doi/10.1016/S1353-8020(09)70842-9&rft_dat=%3Cproquest_cross%3E733657672%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733657672&rft_id=info:pmid/20123565&rft_els_id=S1353802009708429&rfr_iscdi=true |